BRAVE is testing bariatric surgery, versus medical weight management, in severely obese patients (BMI 35 or higher) who have cardiovascular disease including heart failure.

Bariatric surgery is expected expected to reduce weight by 40 kg. on average.

Primary outcome will be major CV events, including HF at 5 years.

In a subset of 200 individuals, we will test its’ impact on cardiac structure and function by echocardiography.

This trial will establish whether weight reduction in obese individuals can reduce HF development or progression.

BRAVE is part of the CHF Alliance, a pan-Canadian heart failure research network.

Study Type

Interventional - Procedure

Study Design

Open-label, parallel-arm RCT

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2021 - 2027



Back To Top